Log In
BCIQ
Print this Print this
 

AT-300 (formerly GsMtx-4, GsMTx4)

  Manage Alerts
Collapse Summary General Information
Company Tonus Therapeutics Inc.
DescriptionSmall molecule inhibitor of cationic stretch-activated ion channels (SACs) derived from the venom of the tarantula Grammostola spatulata
Molecular Target Piezo-type mechanosensitive ion channel component 1 (PIEZO1) ; Piezo-type mechanosensitive ion channel component 2 (PIEZO2)
Mechanism of Action Piezo-type mechanosensitive ion channel component 1 (PIEZO1) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationMuscular dystrophy
Indication DetailsTreat Duchenne muscular dystrophy (DMD)
Regulatory Designation U.S. - Orphan Drug (Treat Duchenne muscular dystrophy (DMD))
PartnerAkashi Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/15/2014

Undisclosed

0

0

Get a free BioCentury trial today